相关实验视频

Updated: Sep 9, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

新辅助化疗对口腔状细胞癌的PD- L1表达的影响:一个匹配的活检切除研究

Deeksha Agrawal¹, Nidhi Anand¹, Nuzhat Husain¹

¹Department of Pathology.

Human pathology

|August 31, 2025

概括

新辅助化疗 (NACT) 在口腔状细胞癌 (OSCC) 中导致编程死亡配体1 (PD- L1) 表达的多种变化. 虽然一些瘤显示PD-L1的减少,但其他瘤则增加了其表达,影响了其作为免疫治疗生物标志物的使用.

科学领域:

癌症学
免疫学
生物标志物研究

背景情况:

编程死亡配体1 (PD- L1) 对于免疫逃避至关重要,也是口腔状细胞癌 (OSCC) 免疫治疗的关键生物标志物.
在新辅助化疗 (NACT) 后了解PD- L1表达变化对于治疗策略至关重要.
这项研究调查了OSCC中NACT后的PD-L1表达转移.

研究的目的:

在NACT后评估OSCC中PD-L1表达的变化.
将这些PD- L1表达变化与临床病理特征相关联.
评估PD-L1作为NACT后的一个生物标志物的临床相关性.

主要方法:

分析了130名OSCC患者 (95名NACT,35名对照).
在NACT前和NACT后的样本上使用免疫组织化学 (SP263克隆) 测量PD- L1表达.
在各种切断点使用瘤比例得分 (TPS),免疫比例得分 (IPS) 和综合阳性得分 (CPS).

主要成果:

在NACT后观察到显著的PD- L1表达变化.
在T1瘤和DOI<5mm的瘤中降低PD-L1TPS.
晚期结节阶段的PD- L1增加,LVI,PNI和瘤芽;与瘤芽,WPOI,DOI和预后阶段相关的CPS变化.

结论:

在OSCC中,NACT不会引起均的PD- L1表达变化.
显著的变化主要是T1瘤TPS和CPS与特定病理特征的相关性.
在NACT后的PD- L1解释需要谨慎;需要进一步研究以确定临床相关性.

关键词:

口腔状细胞癌;PD- L1表达;新辅助治疗;预后;瘤比例得分;综合阳性得分.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...